Disc Medicine Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
IRON$84.64+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(26,949) | $(22,781) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Depreciation and amortization | 26 | 25 |
| Stock-based compensation | 4,058 | 1,024 |
| Noncash lease expense | 142 | 84 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (4,112) | (908) |
| Accounts payable | (7,360) | (10,750) |
| Accrued expenses | 671 | (2,084) |
| Operating lease liabilities | (75) | (76) |
| Net cash used in operating activities | (33,599) | (35,466) |
| Cash flow from investing activities | ||
| Purchases of property and equipment | (67) | (29) |
| Net cash used in investing activities | (67) | (29) |
| Cash flow from financing activities | ||
| Proceeds from sale of common stock in offerings, net of issuance costs paid | — | 34,217 |
| Proceeds from sale of pre-funded warrants in offerings, net of issuance costs paid | — | 28,262 |
| Proceeds from sale of common stock in at-the-market offerings, net of issuance costs paid | 14,849 | 14,605 |
| Proceeds from stock option exercises | 806 | 222 |
| Contributions from employee stock purchase plan | 245 | — |
| Net cash provided by financing activities | 15,900 | 77,306 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (17,766) | 41,811 |
| Cash, cash equivalents and restricted cash, beginning of period | 360,616 | 194,788 |
| Cash, cash equivalents and restricted cash, end of period | $342,850 | $236,599 |
| Supplemental cash flow information | ||
| Cash paid for income taxes | $— | $— |
| Supplemental disclosure of non-cash activities | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $— | $8 |
| Receivable for proceeds from stock option exercises included in other current assets | $— | $845 |
| Deferred issuance costs on sale of common stock and pre-funded warrants in offerings included in accounts payable and accrued expenses | $— | $222 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.